^
No biomarker
Merkel Cell Carcinoma
avelumab
Sensitive: A1 - Approval
No biomarker
Merkel Cell Carcinoma
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Merkel Cell Carcinoma
EP
Sensitive: A2 - Guideline
No biomarker
Merkel Cell Carcinoma
nivolumab
Sensitive: A2 - Guideline
No biomarker
Merkel Cell Carcinoma
cisplatin
Sensitive: A2 - Guideline
No biomarker
Merkel Cell Carcinoma
carboplatin
Sensitive: A2 - Guideline
No biomarker
Merkel Cell Carcinoma
carboplatin + etoposide oral
Sensitive: A2 - Guideline
No biomarker
Merkel Cell Carcinoma
topotecan
Sensitive: A2 - Guideline
No biomarker
Merkel Cell Carcinoma
CAV
Sensitive: A2 - Guideline
No biomarker
Merkel Cell Carcinoma
AST-008
Sensitive: B - Late Trials
ARID2 mutation
Merkel Cell Carcinoma
Immunotherapy
Sensitive: C3 – Early Trials
NTRK1 mutation
Merkel Cell Carcinoma
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 expression
Merkel Cell Carcinoma
avelumab
Sensitive: C3 – Early Trials
PD-1 expression
Merkel Cell Carcinoma
Immunotherapy
Sensitive: C3 – Early Trials
DLL3 expression
Merkel Cell Carcinoma
rovalpituzumab tesirine
Sensitive: C4 – Case Studies
PD-L1 negative
Merkel Cell Carcinoma
avelumab
Sensitive: C4 – Case Studies
NCAM1 expression
Merkel Cell Carcinoma
nivolumab
Sensitive: C4 – Case Studies
NKX2-1 expression
Merkel Cell Carcinoma
avelumab
Sensitive: C4 – Case Studies